524717 — Titan Biotech Balance Sheet
0.000.00%
- IN₹10.45bn
- IN₹10.42bn
- IN₹1.56bn
Annual balance sheet for Titan Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
| C2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | ARS | ARS | ARS | ARS | ARS | 
| Standards: | IAS | IAS | IAS | IAS | IAS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 54.5 | 68.1 | 48.6 | 28.4 | 51.3 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 190 | 166 | 221 | 222 | 207 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 588 | 638 | 683 | 722 | 790 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 338 | 385 | 491 | 545 | 588 | 
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,007 | 1,081 | 1,345 | 1,566 | 1,747 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 193 | 169 | 204 | 191 | 177 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 320 | 218 | 246 | 231 | 213 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 688 | 862 | 1,099 | 1,335 | 1,534 | 
| Total Liabilities & Shareholders' Equity | 1,007 | 1,081 | 1,345 | 1,566 | 1,747 | 
| Total Common Shares Outstanding |